SXTP.US 60 Degrees Pharmaceuticals, Inc. Common Stock

Healthcare Pharmaceuticals USA Stocks
0.5341 USD
Close of Nov 18, 2026
0.4600 5.30
Market cap
USD 1.88M
P/E
-
P/B
-
ROE
-1,094.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SXTP.US undervalued?

Graham number

The Graham number of 60 Degrees Pharmaceuticals, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

60 Degrees Pharmaceuticals, Inc. Common Stock fundamental analysis

No fundamental analysis for 60 Degrees Pharmaceuticals, Inc. Common Stock yet.

60 Degrees Pharmaceuticals, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About 60 Degrees Pharmaceuticals, Inc. Common Stock

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and …

Full company profile